Current Partnership:

HDAC Program – MethylGene, Inc.

MethylGene is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics with an initial focus on cancer and infectious disease.

EnVivo and MethylGene have begun an exclusive collaboration agreement to discover, develop and commercialize therapeutics for the treatment of neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Huntington’s diseases using MethylGene’s isotypic selective, small molecule, histone deacetylase (HDAC) inhibitors. Under the agreement, MethylGene will contribute its proprietary chemistry expertise to develop small molecule HDAC inhibitors in a collaboration that utilizes EnVivo’s proprietary in vivo models and drug discovery platform for neurodegenerative diseases.

Out-Licensing Opportunities:

1. Current programs

Alzheimer’s disease

  • Nicotinic Acetylcholine Receptor Agonist Program for cognitive enhancement
    • Phase 1 studies to start in Q3 2006

Various neurodegenerative diseases

  • EVPK-0003546 Program
    • Initial compound is a repurposed generic drug that has shown efficacy in EnVivo’s transgenic Huntington’s disease Drosophila and mouse models.
    • Phase 1 studies to start in Q3 2006
  • EVP-0002442 Program
    • The compound has shown efficacy in EnVivo’sDrosophila models in Alzheimer’s and Huntington’s diseases.
    • The compound also appears to be active in mammals in vivo.

2. Screening in neurodegenerative diseases

Partner provides stratified chemical libraries for screening in existing EVP Drosophila neurodegeneration models

3. New models/screening

EnVivo creates humanized Drosophila models based on novel genes provided by partner

  • Functional elucidation
  • Proprietary assay development and screening

4.Target identification and mechanism of action studies

Partner provides compounds for target identification and mechanism of action studies in current Drosophila models

  • Functional genomics (modifier screens)
  • Chemical genomics


EnVivo is currently seeking in-licensing opportunities in the CNS field that are in late preclinical or early clinical stage.